Fulgent Genetics News

Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024

EL MONTE, Calif.--(BUSINESS WIRE)--Apr. 11, 2024-- Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business a

Fulgent GeneticsApr 11 00:00 ET

Reproductive Genetics Market Analysis Report 2024-2032, Featuring Bangkok Genomics Innovation, Centogene, Fulgent Genetics, Igenomix, Invitae, PerkinElmer and Thermo Fisher Scientific

Yahoo FinanceMar 28 11:33 ET

Fulgent Genetics Is Maintained at Neutral by Piper Sandler

Fulgent Genetics Is Maintained at Neutral by Piper Sandler

Dow JonesMar 6 09:42 ET

Express News | Piper Sandler Maintains Neutral on Fulgent Genetics, Lowers Price Target to $25

Moomoo 24/7Mar 6 09:31 ET

Fulgent Genetics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/06/2024 7.67% Piper Sandler $28 → $25 Maintains Neutral 12/07/2023 50.73% UBS → $35 Initiates Coverage

BenzingaMar 6 09:31 ET

Piper Sandler Sticks to Its Hold Rating for Fulgent Genetics (FLGT)

TipRanksMar 6 07:36 ET

Revenues Not Telling The Story For Fulgent Genetics, Inc. (NASDAQ:FLGT)

When you see that almost half of the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S") below 0.9x, Fulgent Genetics, Inc. (NASDAQ:FLGT) looks to be giving

Simply Wall StMar 1 09:41 ET

An Intrinsic Calculation For Fulgent Genetics, Inc. (NASDAQ:FLGT) Suggests It's 32% Undervalued

Yahoo FinanceMar 1 06:19 ET

Fulgent Genetics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Yahoo FinanceMar 1 05:48 ET

UBS Adjusts Fulgent Genetics Price Target to $25 From $35, Maintains Neutral Rating

UBS Adjusts Fulgent Genetics Price Target to $25 From $35, Maintains Neutral Rating.

MT NewswiresFeb 29 13:00 ET

Express News | Fulgent Genetics Shares Are Trading Lower After the Company Reported Q4 Financial Results and Issued FY24 Guidance Below Estimates

Moomoo 24/7Feb 28 12:07 ET

Earnings Call Summary | Fulgent Genetics(FLGT.US) Q4 2023 Earnings Conference

The following is a summary of the Fulgent Genetics (FLGT) Q4 2023 Earnings Call Transcript:Financial Performance:Fulgent Genetics reported Q4 revenue of $70 million, an increase compared to Q4 2022's

moomoo AIFeb 28 11:43 ET · Conference Call

Fulgent Genetics Inc (FLGT) Faces GAAP Loss Despite Core Revenue Growth in 2023

Yahoo FinanceFeb 28 07:35 ET

Fulgent Genetics Shares Business Insights in Investor Update

TipRanksFeb 28 07:22 ET

Express News | Fulgent Genetics Expects 2024 Core Revenue of Approximately $280M Versus Consensus Of $294.25M, With Adjusted EPS Loss Of Approximately $(1.05) Versus Consensus Of $(0.95)

Moomoo 24/7Feb 28 07:05 ET

Express News | Fulgent Genetics Q4 Adjusted EPS $0.28 May Not Be Comparable To $(0.29) Estimate, Sales $70.50M Beat $66.32M Estimate

Moomoo 24/7Feb 28 07:02 ET

Press Release: Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results

Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results -- Full Year 2023 Total Revenue of $289.2 million; Q4 2023 Total Revenue of $70.5 million -- Full Year 2023 Core Reve

Dow JonesFeb 28 07:02 ET

Fulgent Genetics 4Q Loss $128.1M >FLGT

Fulgent Genetics 4Q Loss $128.1M >FLGT

Dow JonesFeb 28 07:00 ET

Earnings Scheduled For February 28, 2024

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. • Golden Ocean Group (NASDAQ:GOGL) is likely to report

BenzingaFeb 28 06:24 ET

Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results

Full Year 2023 Total Revenue of $289.2 million; Q4 2023 Total Revenue of $70.5 million Full Year 2023 Core Revenue grows 44% year-over-year to $262.1 million; Q4 2023 Core Revenue grows 21% year-ove

Fulgent GeneticsFeb 28 00:00 ET